Skip to main content

Table 6 Changes in serum cystatin C [the final evaluation pointa-R20 (week 20 of the Run-in period)] comparison of TRK-100STP groups versus placebo analyzed by the ANCOVA model

From: Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

Treatment group

Number of patientsb

Least square mean of the difference in serum cystatin C (mg/L)

Difference in the least square mean (versus placebo) (mg/L)

P-value

Point estimate

SE

Point estimate

SE

Placebo

32

0.253

0.065

―

―

―

120 μg

31

0.097

0.066

0.157

0.092

0.0928

240 μg

35

0.052

0.063

0.201

0.090

0.0285

  1. aAt Week 28 of the treatment period or when treatment was discontinued
  2. bDifferent from FAS because some patients lacked value of cystatin C